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Summary 
Zoonotic orthopoxvirus (OPV) can induce severe disease in man and the virus has potential for use in 
bioterrorism. New vaccines and therapeutics against OPV infections must be tested in animal models. 
The aim of this study was to characterize the clinical course and pathology of a new OPV isolate, 
calpox virus, which is infectious in marmosets. Infection experiments were performed with 28 common 
marmosets (Callithrix jacchus) exposed to different challenge doses of calpox virus by the intravenous, 
oropharyngeal and intranasal (IN) routes. The median marmoset IN infectious dose corresponded to 
8.3 × 10
2
 plaque forming units of calpox virus. Infected animals developed reproducible clinical signs 
and died within 4–15 days post infection. Characteristic pox-like lesions developed in affected organs, 
particularly in the skin, mucous membranes, lymph nodes, liver and spleen. Calpox virus disease 
progression and pathological findings in the common marmoset appear to be consistent with lethal 
OPV infections in man and in other non-human primate (NHP) models. IN inoculation with low virus 
doses mimics the natural route of the human variola virus infection. Thus, the marmoset model of 
calpox virus infection can be considered to be relevant to investigation of the mechanisms of OPV 
pathogenesis and pathology and for the evaluation of new vaccines and antiviral therapies. 
 
Introduction 
In addition to possible intentional release of variola virus (VARV) as a biological weapon, the 
increasing zoonotic potential of orthopoxviruses (OPVs) has recently become of concern (LeDuc and 
Jahrling, 2001). Both cowpox virus (CPXV) ( [Chantrey et al., 1999] and [Campe et al., 2009]) and 
monkeypox virus (MPXV) have crossed the species barrier to man ( [DiGiulio and Eckburg, 
2004] and [Parker et al., 2007]). Naturally occurring OPV diseases are of growing concern because 
the number of people with vaccinia virus (VACV)-induced immunity is declining. MPXV is endemic in 
Western and Central Africa and outbreaks of human MPXV resemble smallpox infection (Nalca et al., 
2005). More recently, an outbreak of human MPXV infection was reported in the Midwest of the USA 
(Centers for Disease Control and Prevention, 2003). CPXV infections are presently limited to Europe 
and Asia. Human CPXV infections acquired from pet rats or other pet or zoo animals are reported in 
increasing number ( [Baxby et al., 1979], [Baxby et al., 1994], [Pilaski et al., 1986], [Vorou et al., 
2008] and [Campe et al., 2009]) and the number of animal species susceptible to CPXV is increasing 
similarly. Field and experimental studies have indicated that CPXV has a broad host range and 
maintains a reservoir in wild rodents. CPXV is endemic in bank voles (Myodes glareolus) and wood 
mice (Apodemus sylvaticus), which serve as the main reservoirs (Begon et al., 1999). Furthermore, 
the virus is often isolated from domestic cats, which should be regarded as a potential source of 
infection in urban areas ( [Baxby et al., 1979], [Chantrey et al., 1999] and [Hazel et al., 2000]). The 
majority of human CPXV and MPXV infections have a mild course, leading to localized, often self-
limiting skin lesions with low morbidity (Campe et al., 2009). However, hospitalization of CPXV-
infected individuals is reported and immunosuppressed individuals are at particular risk of developing 
  
severe complications, including disseminated infection and death ( [Eis-Hübinger et al., 
1990] and [Czerny et al., 1991]). 
Waning herd immunity because of discontinuation of smallpox vaccination is probably contributing to 
the increased incidence of OPV infections in man, particularly in younger age groups, with more 
severe courses of clinical infection (Kurth et al., 2009). In addition, increasing global travel and 
importation of exotic animal species from OPV-endemic areas increases the risk of OPV transmission. 
The development of new vaccines with low side-effects and efficient antiviral drugs is needed to 
counteract the risk of zoonotic OPV infections. Research into therapeutic agents for prevention and 
treatment of OPV infections requires adequate animal models to investigate the efficacy and safety of 
new vaccines and antiviral compounds. The two-animal rule of the US Food and Drug Administration 
states that efficacy and safety studies must be performed in more than one animal species, one of 
which should preferably be non-human primates (NHPs). Currently, the most common animal models 
for studying OPV infections are murine models of ectromelia virus (ECTV) and VACV infections. The 
best species in which to study human disease, virus pathology, vaccines and antiviral compounds are 
NHPs. At present two NHP models are established. These are MPXV infection of cynomolgus 
macaques (Macaca fascicularis) (Hooper et al., 2004) and rhesus macaques (Macaca mulatta) 
(Stittelaar et al., 2005) as well as VARV infection of cynomolgus macaques (Jahrling et al., 2004). 
A major limitation of all macaque models is that very high infectious doses must be administered, 
primarily by intravenous (IV) administration in order to induce severe disease. For the cynomolgus 
macaque model of VARV infection, 10
9
 plaque forming units (pfu) given IV are required to cause 
typical smallpox signs with a mortality of at least 33% (Jahrling et al., 2004). The rhesus macaque 
model of MPXV infection uses different inoculation routes including IV, intranasal (IN), subcutaneous 




 pfu to induce 
clinical disease. Inoculation with doses <10
6
 pfu results in a milder course of disease, which most 
animals survive ( [Zaucha et al., 2001], [Hooper et al., 2004], [Stittelaar et al., 2005], [Stittelaar et al., 
2006] and [Saijo et al., 2006]). Additionally, working with MPXV and VARV is technically challenging, 
as it requires biosafety level 3 or 4 laboratories, respectively. Furthermore, macaques are relatively 
expensive animals compared with marmosets. Therefore, it would be useful to develop a new NHP 
model in which infections with OPVs other than VARV and MPXV induced a disease comparable to 
human smallpox. 
In 2002 a lethal atypical epizootic OPV infection was reported in a colony of 80 New World monkeys in 
Lower Saxony, Germany (Mätz-Rensing et al., 2006). Sequencing and molecular characterization 
identified the virus as a new CPXV named calpox virus, after its host Callithrix jacchus, the common 
marmoset (Ellerbrok, unpublished data). Phylogenetic analyses revealed that this virus is related to, 
but distinct from known CPXV strains, which form a heterogeneous group of viruses within the genus 
Orthopoxvirus. The analysis of the natural outbreak in 2002 suggested that this virus infection in the 
common marmoset could serve as a valuable model system for smallpox virus infection of man. 
Therefore, the aim of the present study was to characterize the clinical course and pathology of calpox 
virus infection of common marmosets. 
 
 
Materials and Methods 
Animals 
Twenty-eight healthy, sexually mature, common marmosets of different ages and sexes were obtained 
from the breeding colony of the German Primate Center (Table 1). During the experiments the animals 
were housed in single cages (130 × 53 × 80 cm) with olfactory and acoustic contact with each other. 
They were allowed free access to food and water and had routine environmental enrichment. Animal 
rooms were maintained at 25°C on a 12 h light and dark cycle. Marmosets were fed primate pellets 
every day, supplemented by fruit and commercial paps. All animals were fed, tended and maintained 
according to the German Animal Protection Act. All animal experiments were approved by the 
responsible veterinary authorities (approval numbers 33.42502/08-07.05, 33.42502-04-019/07 and 
33.42502/08-02.04) and performed in accordance with EU guidelines for the accommodation and care 
of animals used for experimental and other scientific purposes. Animals were checked clinically twice 
daily. Blood samples were collected twice weekly. Moribund or terminally ill animals were humanely 
  
sacrificed using an overdose of barbiturates. Complete necropsy examinations were performed on all 
animals, either after destruction or immediately after they were found dead. A complete range of 
organs was collected for microscopical, electron microscopical and virological investigations. 
 
Virus and Infection 
The calpox virus was propagated in Hep2 cells and stored in aliquots at −70°C. The median tissue 
culture infectious dose of the virus stock was determined by plaque assay before use in the infection 
experiments. The marmosets were infected by the IV, oropharyngeal (ORO) or IN route with different 
infectious doses of calpox virus (Table 1). For virus administration, marmosets were anaesthetized by 
intramuscular injection of 0.1 ml per 200 g body weight of a mixture of 5% ketamine, 1% xylazine and 
0.01% atropine. Calpox virus was administered IV into the saphenous vein in a volume of 500 μl. ORO 
virus administration was performed by dropping 100 μl of the virus solution into the rear of the oral 
cavity. IN inoculation was carried out by pipetting 50 μl virus solution into each nostril. 
 
Microscopy 
Tissue samples were fixed in 10% neutral buffered formalin and processed routinely. Sections were 
stained with haematoxylin and eosin (HE) using the Varistain Gemini automated stainer (Thermo 
Fisher Scientific, Frankfurt/Main, Germany). Sections of selected tissue samples were analyzed by 
immunohistochemistry (IHC) for detection of virus antigens using human anti-VACV immunoglobulin 
(Omrigam 5%; 1 in 500 dilution) as the primary antibody and goat anti-human immunoglobulin (Ig) G 
antibody conjugated to biotin (Invitrogen, Darmstadt, Germany; 1 in 500 dilution) as secondary 
reagent. IHC was performed by use of a NexES-IHC staining module (Ventana, Illkirch, France). 
Selected sections of skin and liver samples were processed for transmission electron microscopy 




In order to prove that the calpox virus isolate induced a disease comparable to that observed in the 
natural outbreak in a New World monkey colony, eight test animals were inoculated IV with 
1.3 × 10
7
 pfu (animals 1–3), 1.0 × 10
4
 pfu (animals 4–6) or 1.25 × 10
7
 pfu (animals 7 and 8). IV 
inoculation of the virus led to a rapidly developing fulminant disease at all three doses. All animals died 
between 4 and 7 days post infection (dpi). 
The first clinical signs were respiratory difficulty, depression and anorexia, which preceded death by 
1 day. Gross necropsy examination showed that all eight animals had lesions identical to those 
reported in the natural outbreak and comparable to those described in other OPV infections. Some 
animals developed moderate SC oedema of the pharyngeal region. They began to show evidence of a 
mild exanthema and enanthema at 5 dpi. Cutaneous erythema or single small macular lesions 
appeared on the face, trunk and mucous membranes. Single macules developed into small papular or 
vesicular lesions depending on the survival time of the host. The papular skin lesions appeared as 
pale tan to white foci that later became reddened and slightly raised, reaching a diameter of 2–3 mm 
(Fig. 1). They were often found in association with focal dermal haemorrhages. The average number 
of skin lesions found on one animal was approximately 10, with distribution mostly over the facial 
region, ventral abdomen and inguinal areas. All marmosets developed splenic lymphoid hyperplasia 
and marked lymphadenomegaly of submandibular, axillary and inguinal lymph nodes accompanied by 
moderate haemorrhage of these nodes. Acute moderate transmural haemorrhage occurred in the 
large intestine of all animals, often in association with haemorrhagic mesenteric lymph nodes (Fig. 2). 
Acute moderate mucosal haemorrhage was observed within the urinary bladder (animals 3–8) and 
acute moderate to severe haemorrhage occurred in the liver (animals 1–5) and testes (animal 7). 
  
Microscopically, the most prominent finding was multifocal vesicular dermatitis, with cutaneous and SC 
haemorrhage affecting the skin and haemorrhages of the oral mucosa. The cutaneous lesions were 
characterized by focal epidermal necrosis, acanthosis and acantholysis leading to vesiculation typical 
of human pox-related exanthema (Fig. 3). Individual cell necrosis occurred within the stratum basale 
and the deep stratum spinosum. There was a sparse infiltration of the affected epidermis with 
neutrophils admixed with cellular debris. Multinucleated syncytial keratinocytes were observed 
occasionally in the epithelium of the skin and the mucous membranes adjacent to areas of necrosis 
and degeneration. Haemorrhage into the vesicles was occasionally observed. Follicular and 
sebaceous epithelia were also affected, developing single cell necrosis and inflammatory cell 
infiltration, whereas apocrine glands were spared. 
Numerous characteristic intracytoplasmic inclusion bodies (Guarnieri bodies) were found in enlarged 
vacuolated or degenerate cells (Fig. 3). The Guarnieri bodies measured 2–8 μm and were distributed 
randomly within the altered epithelium. Virus antigen was detected most frequently within altered 
keratinocytes in dermal lesions. 
The liver contained disseminated foci of acute haemorrhage and swollen hepatocytes with vacuolated 
cytoplasm, cytoplasmic inclusion bodies and single cell necrosis (Fig. 4). There was a moderate 
generalized circulating neutrophilia. Splenitis occurred as foci of necrosis centered on the germinal 
centres of the lymphoid follicles. These structures were infiltrated by macrophages and neutrophils 
admixed with cellular debris. Lymphoid hyperplasia was present in otherwise unaffected lymphoid 
follicles. The inguinal lymph nodes showed a severe necrotizing lymphadenitis accompanied by 
haemorrhage. Other lymph nodes had follicular hyperplasia with activation of the germinal centres. 
Within the colon and small intestine of all animals there was severe acute focal transmural 
haemorrhage (Fig. 5) and focal erosive enteritis. Severe acute diffuse interstitial haemorrhage was 
found within the testes of one animal (Fig. 6) and there was multifocal haemorrhage within the mucosa 
of the urinary bladder of two animals. 
Calpox virus genetic material was detected in all investigated tissues of the eight marmosets by 
quantitative real-time polymerase chain reaction (PCR). The detection of high copy numbers of viral 
DNA and mRNA in all tissues indicated a fulminant and generalized infection of marmosets infected by 
the IV route (Kramski et al., 2010). 
 
Oropharyngeal Infection 
Five marmosets were inoculated with 2.5 × 10
7
 pfu of virus by the ORO route. Only one animal 
(number 9) showed clinical signs of infection and was humanely sacrificed at 13 dpi because of 
marked dyspnoea caused by severe laryngeal oedema and papulovesicular laryngitis. Calpox virus 
was detected in the blood of this animal by PCR. All other organs were unaffected. The other animals 
of this group remained healthy with no signs of infection. Calpox virus was not detected in the blood 
and virus-specific antibodies were not detected in the serum over a period up to 42 dpi by use of an 
indirect immunofluorescence assay (Kurth et al., 2009). 
 
Intranasal Infection 
Six groups of two animals were each inoculated IN with different doses of virus (Table 1). Two 
marmosets were inoculated with 2.3 × 10
6
 pfu (animals 10 and 11) and two marmosets were given 
3.5 × 10
5
 pfu (animals 12 and 13). In all four animals a lethal course of disease was induced. All four 
animals developed typical clinical signs of generalized OPV infection and died at 9–10 dpi. The next 
group of animals was given 3.5 × 10
4
 pfu (animals 14 and 15), 3.5 × 10
3
 pfu (animals 16 and 17), 
5.0 × 10
2
 pfu (animals 18 and 19) and 1.0 × 10
2
 pfu calpox virus (animals 20 and 21) (Table 1). 
Animals 14–17 developed less pronounced alterations compared with the first four animals inoculated 
IN. All four animals were humanely sacrificed at 14 dpi. The expression of exanthema and enanthema 
was greater in the two animals given the higher dose (animals 14 and 15). From the lowest dose 
group (animals 18–21) only one animal (number 18) became infected. None of the three surviving 
marmosets showed any signs of infection or developed virus-specific antibodies (data not shown). 
Two of them were successfully reinoculated with a higher dose of virus (animals 19 and 20). Both of 
  
these animals developed typical clinical signs of poxvirus infection after reinoculation with 
3.5 × 10
3
 pfu and died 14 days after reinoculation. Animal 21 did not show any signs of infection. 
The lethal dose of 8.3 × 10
3
 pfu deducted from the limited in-vivo titration described above was 
administered to seven animals (animals 22–28) by the IN route. These animals served as controls in 
several subsequent vaccination studies. The first clinical signs were noticed at 10 dpi. Infected animals 
showed respiratory difficulty accompanied by nasal discharge. All seven animals died between 10 and 
15 dpi. 
Gross necropsy examinations revealed changes that were almost identical to those induced by IV 
infection. There was marked SC oedema and erythema of the face and the neck region, varying in 
degree depending on the infectious dose and time. Confluent or single smallpox-like vesicular lesions 
were scattered on the skin of the face (Fig. 7 and Fig. 8), abdomen and thighs. Typical haemorrhagic 
and umbilicated vesicular lesions distributed over the face, body and thighs were seen in animals 
given the lethal dose of 8.3 × 10
3
 pfu (Fig. 9). Additionally, there was severe ulceration of the mucous 
membranes, particularly affecting the gingiva, tongue and larynx. Whereas few lesions were observed 
on the skin of animals infected via the IV route, 20–30 single vesicules or papules were counted on 
each animal infected by the IN route. Furthermore, moderate splenomegaly, alveolar oedema in the 
lung, oedema of the tonsils, lymphoid hyperplasia with focal haemorrhage and acute necrosis of the 
submandibular and retropharyngeal lymph nodes was observed. Haemorrhagic cystitis was a frequent 
finding in animals given the lethal dose of 8.3 × 10
3
 pfu, indicating a severe systemic infection. No 
specific lesions were detected in the heart, skeletal muscle, lung, kidney, nervous system, eye or 
brain. 
Microscopical investigation of the tissues revealed typical vesicular skin lesions characterized by focal 
necrosis, acantholysis, acanthosis, syncytia formation of the basal keratinocytes and accumulation of 
Guarnieri bodies in altered epithelial cells accompanied by haemorrhage (Fig. 10 and Fig. 11). Minimal 
haemorrhage and severe congestion were found in the lung and liver. Hepatocellular swelling and 
vacuolation was a consistent finding. Hepatocyte nuclei varied in size and these cells sometimes had 
multiple nuclei or mitoses or single cell necrosis. Endothelial cells lining sinusoids were swollen and 
necrotic. Hyperplastic follicles were noted within the enlarged spleen and lymph nodes. The 
submandibular and retropharyngeal lymph nodes had severe necrotizing inflammation accompanied 
by haemorrhage and accumulation of apoptotic cells in the remains of follicles. All other tissues lacked 
specific pathological changes. 
 
Immunohistochemical and Ultrastructural Findings 
IHC and electron microscopy confirmed the presence of calpox virus-infected cells in different tissues. 
OPV antigens were visualized in the skin, liver and lymph nodes. In cutaneous lesions the virus was 
present in degenerate epithelial cells, dermal macrophages and altered sebaceous glands 
(Fig. 12 and Fig. 13). In lymphoid tissue, virus antigen was found in monocytes, macrophages and 
endothelial cells. Virus antigen was also detected in the liver beneath foci of affected hepatocytes. 
Electron microscopy revealed virus particles with OPV-like morphology in intracytoplasmic inclusions 
in epithelial cells and liver cells. 
Ultrastructurally, intracytoplasmic inclusions were comprised of mature virus particles measuring 
140 × 260 nm (Fig. 14). The enveloped virus particles were ovoid to brick-shaped with a pale central 
zone, having features characteristic of OPV (Fig. 15). 
The virus load in tissue samples of all animals inoculated IN reached virus titres vastly in excess of the 
viral inocula (Kramski et al., 2010). The virus distribution and final viral loads were comparable to the 
IV infection experiments. In brief, the highest loads of virus DNA were found in the skin, lung, spleen, 
lymph nodes, oesophagus and tonsils (>10
5
 calpox genome equivalents/10
4
 copies of the c-myc gene) 
in all animals infected via the IN route. 
  
Discussion 
This report describes the microscopical and ultrastructural changes in marmosets infected 
experimentally with calpox virus. Calpox virus is a new CPXV isolated from a lethal OPV outbreak in 
New World monkeys (Mätz-Rensing et al., 2006). In natural VARV and MPXV infections, unvaccinated 
human patients generally develop symptoms and some infected individuals die. However, all the 
marmosets exposed to calpox virus and demonstrating productive infection developed clinical signs 
and died from infection, independent of the route of inoculation. Serological and microbiological 
investigations have shown that these animals do not have underlying immunodeficiency, which might 
explain their high susceptibility and the lethal outcome of the infection. Calpox virus-exposed animals 
that remained healthy were negative for virus genomic DNA and virus-specific antibodies, suggesting 
an unsuccessful infection. 
As natural VARV transmission is primarily by aerosol, we sought to investigate natural routes of 
infection (Esposito and Fenner, 2001). The main route of virus transmission via the respiratory tract 
was mimicked by IN application of the virus. Viral doses as low as 5 × 10
2
 pfu led to lethal infection in 
approximately one-third of the inoculated animals (data not shown). An infectious dose of around 
8 × 10
3
 pfu, derived from limited in-vivo titration, reproducibly led to disease with similar signs to those 
observed in the natural outbreak (Mätz-Rensing et al., 2006). 
The clinical and pathological features of the disease in marmosets were comparable in many aspects 
to human VARV infection ( [Fenner et al., 1988] and [Esposito and Fenner, 2001]). Different clinical 
manifestations of VARV infection are reported. The most common clinical form produced by both 
VARV major and minor is the ordinary type. According to the severity of the rash on the face and 
upper limbs, ordinary smallpox is subdivided into the confluent subtype (confluent rash on face and 
forearms), the semi-confluent subtype (confluent rash on face and discrete rash elsewhere) and the 
discrete subtype (areas of normal skin between the pustules). The modified type is usually non-fatal 
and the rash evolves quickly with more variation in lesion size than in discrete ordinary smallpox. In 
the flat type, confluent or semi-confluent pustules remain flat, soft and non-suppurative. Widespread 
haemorrhages in skin and mucous membranes are characteristic for the haemorrhagic type. The flat 
type and the haemorrhagic type of VARV major are usually fatal. Independent of the route of infection, 
all experimentally infected marmosets died within 1–2 days after onset of clinical signs. In contrast to 
the VARV infection, no recovery from the disease after onset of clinical signs was observed. 
Independent of the dose of infection, all infected animals developed typical clinical signs of OPV 
infection. Characteristic pathological features in the monkeys were severe oedema of the neck region, 
focal epithelial and mucosal lesions characterized by severe epidermal haemorrhage and vesiculation 
induced by epidermal acantholysis. Ulcerative mucosal lesions were found on the gingiva, the tongue 
or in the pharyngeal region and less consistently on the mucous membranes of the oesophagus and 
urinary bladder. As in human smallpox infection, the rash appeared first in the mouth, on the pharynx, 
face and forearms and then spread to the trunk and legs. Lesions rarely appeared on the palms and 
soles, which is in contrast to smallpox. The rash became vesicular and then pustular within 1–2 days. 
Typical pustules with crust formation were not observed in monkeys. Unlike MPXV and VARV patients 
who develop a more or less confluent rash ( [Jezek et al., 1987], [Fenner et al., 1988] and [Parker 
et al., 2007]), the number of papules was sparse. After IV inoculation, less than 10 typical papules 
were found. In contrast, after IN inoculation the number of cutaneous papules and vesicles increased 
up to 20 small lesions. After IV infection, cutaneous alterations were less pronounced compared with 
those of animals infected IN, probably due to the shorter incubation period. After IV infection the 
disease took a more haemorrhagic course with bleeding into the skin or the gastrointestinal tract, 
comparable to the haemorrhagic type of smallpox infection in man. Predilection sites of the cutaneous 
lesions were the face, abdomen and thighs. 
Even a high calpox virus dose was not able to induce an infection featuring skin lesions that were 
distributed confluently over the body of the animals, a characteristic previously demonstrated in 
macaques infected with MPXV and VARV, when more than 500 cutaneous lesions were counted ( 
[Hooper et al., 2004], [Jahrling et al., 2004] and [Stittelaar et al., 2005]). The clinical picture of calpox 
virus infection further differed in the morphology of the skin lesions, which remained flat and small in 
size (2–5 mm in diameter), whereas VARV induced more confluent lesions, which reached a diameter 
of >10 mm. The lesions were comparable with the flat type of VARV infection. 
  
The presence of numerous huge eosinophilic granular intracytoplasmic inclusion bodies in the 
cutaneous and mucosal lesions within degenerate keratinocytes is a consistent histological finding in 
both diseases. Immunohistochemical investigations revealed that OPV antigens were only detectable 
in tissues showing morphological alterations and were most prominent within epithelial cells, 
macrophages and endothelial cells. This finding demonstrates that the antigen concentration must be 
above a certain threshold, as quantitative PCR showed that virus genomes could be detected in all 
tissues investigated (Kramski et al., 2010). The presence of OPV antigen correlated with the detection 
of virus particles by electron microscopy. Virus particles showed OPV-like morphology within 
intracytoplasmic inclusions. 
Further typical findings in the marmosets infected with calpox virus were necrotic foci in the spleen and 
liver. The mucosa of the urinary bladder also seems to be a predilection site for infection. In contrast, 
alterations of the urinary bladder or hepatic involvement are uncommon features of the experimental 
MPXV infection in other animal models (Zaucha et al., 2001). In this aspect the new marmoset model 
could offer more insight into the complex pathogenesis of systemic orthopox infection. 
Pathogenetically, it was assumed that the nasal epithelium and the nasal-associated lymphoid tissue 
(NALT) served as a principal target for primary infection following IN infection. The severity of the 
lesions within the laryngopharyngeal area and tonsils in the early course of the disease suggested that 
these organs were additional, although subordinate, sites of primary replication. The distribution of 
lesions was consistent with lymphatic spread to the submandibular and axillary lymph nodes and 
systemic dissemination of the virus through a monocyte-associated viraemia, resulting in lesions 
affecting other lymph nodes, the spleen, liver, skin, oral mucosa, gastrointestinal tract, the 
reproductive system and bladder. The mononuclear phagocyte/dendritic cell system, as demonstrated 
by IHC, was the principal target within lymphoid tissues and may also have provided the means of 
entry into other systemic sites. 
In contrast, experimental IV inoculation of the virus seemingly bypassed the early stages in the 
pathogenesis, namely the initial transmission and infection of primary target tissue, the incubation 
period and the associated prodrome. The IV infection presumably resembled the viraemia, leading to a 
rapid systemic course of the infection with haemorrhagic lesions in several organs. 
Death may have resulted from a massive secretion of cytokines associated with circulating immune 
complexes and soluble calpox virus antigens as well as overwhelming virus replication in the organs in 
the second phase of viraemia, all leading to multiple organ failure. To improve the understanding of 
calpox virus pathogenesis, further research is needed. Newly established marmoset-specific cytokine 
real-time PCR assays may become a useful tool for the determination of the marmoset cytokine 
expression pattern during infection and vaccination studies. 
In most NHP models using VARV or MPXV, IV inoculation, a non-physiological route of infection 
bypassing the mucosa, is used ( [Jahrling et al., 2004], [Rubins et al., 2004] and [Edghill-Smith et al., 
2005]). In these NHP models the IV inoculation route circumvents a primary replication of the virus in 
regional lymph nodes and the successive systemic spread via the lymphatic system (first viraemia). 
Instead, the virus is immediately spread via the bloodstream, inducing a disease with numerous 
lesions characteristic of a post-secondary viraemia. In addition to employing a non-physiological route 
of infection, another major drawback in established NHP models is that the virus has to be 
administered in very high doses to induce a severe or fatal disease. At least 10
6
 pfu of MPXV must be 
injected SC to induce a lethal infection in cynomolgus macaques (Saijo et al., 2006), and IV 
inoculation of at least 5 × 10
7
 pfu of MPXV led to a fatal infection in cynomolgus and rhesus macaques 
( [Earl et al., 2004] and [Hooper et al., 2004]). The three inoculation routes established for the MPXV 
macaque model that come closest to the natural route of smallpox infection were IT ( [Stittelaar et al., 
2005] and [Stittelaar et al., 2006]), aerosolized (Zaucha et al., 2001) and IN administration of MPXV 
(Marriott, 2008).Even so, very high doses of 10
7
 pfu are needed to induce a severe or lethal infection. 
This is similar to the VARV macaque model where extremely high virus doses of at least 10
8
 pfu given 
IV are needed to induce a systemic infection ( [Jahrling et al., 2004] and [Rubins et al., 2004]). 
In the present NHP model, IN application mimicking natural OPV infection proved to be a successful 
strategy for administering calpox virus to marmosets. An association was observed between the 
infectious dose and the course of infection. High virus doses of 2.3 × 10
6
 and 3.5 × 10
5
 pfu rapidly led 
to death within 9–10 days, associated with high viral loads in blood (data not shown). Using 
  
decreasing infectious doses of calpox virus, a median 50% monkey infectious dose (MID50) of 
8.3 × 10
2
 pfu was estimated, showing that calpox virus is highly pathogenic for marmosets. This MID50 
is approximately 10,000 times lower than that needed in any other NPH model for OPV infection and 
might be closer to naturally acquired VARV and MPXV infections. Therefore, the low MID50 needed for 
induction of disease and pathology similar to that induced by MPXV or VARV infection implies that the 
calpox virus/marmoset model is reliable and might have several advantages compared with other NHP 
model systems. 
Epidemiological investigations of the natural calpox virus outbreak in the colony of New World 
monkeys gave no evidence for a transmission to man, even when there was close contact with 
diseased animals. Sequence similarities of the calpox virus to published CPXV sequences allow 
calpox virus to be defined tentatively as the species CPXV in the genus OPV. CPXV is classified as a 
biosafety level 2 pathogen so experiments with this virus may be performed by a larger number of 
laboratories. Whereas some human patients or experimental animals infected with VARV or MPXV 
developed symptoms and then recovered, all diseased marmosets died or had to be humanely 
sacrificed. Animals surviving virus inoculation showed neither clinical nor immunological nor molecular 
markers of an infection. The readout of the success or failure of vaccines or therapeutic treatments is 
therefore straightforward in comparison to other NHP models, and there is no need to develop a 
scoring system for clinical signs. 
Further advantages of using marmosets as experimental animals include their small size, reasonably 
sized housing space and easy handling. These animals can be socially housed, they reproduce well in 
captivity, are inexpensive to keep, have an economical purchase price and wild populations are not 
endangered. As the calpox virus/marmoset model overcomes major limitations of current primate 
models, it is suitable for studying virus pathology and for evaluating new vaccines and antiviral 
therapies. Since New World monkeys seem to be highly susceptible to the infection, the model could 
also help to deal with the disease in captive populations. 
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Tables and Figures 
 
Table 1. Inoculation route, inoculation dose 
and gross pathological findings in animals 
inoculated experimentally with calpox virus. 
 
  
Figure 1. Animal number 6 showing moderate multifocal papular dermatitis of the upper lip (arrows) 
after IV calpox infection. 
 
 
Figure 2. Severe petechiae of the large intestine after IV calpox infection of animal number 6. 
 
  
Figure 3. Acute focal vesicular dermatitis with acanthosis, acantholysis and early vesiculation with 
characteristic intralesional Guarnieri bodies (arrow) after IV calpox infection of animal number 4. HE. 
Bar, 50 μm. 
 
 
Figure 4. Acute focal necrotizing hepatitis with haemorrhage after IV calpox infection of animal 
number 5. HE stain. Bar, 50 μm. 
 
  
Figure 5. Acute multifocal haemorrhage within the mucosa of the large intestine after IV calpox 
infection of animal number 7. HE. Bar, 100 μm. 
 
 
Figure 6. Acute multifocal haemorrhage within the testis after IV calpox infection of animal number 7. 
HE. Bar, 200 μm. 
 
  
Figure 7. Severe erythema and vesicular alterations around both nostrils (arrow), the eyelid and within 




Figure 8. Moderate erythema and single vesicular alterations around both nostrils (arrows) 
accompanied by severe oedema of the neck after IN calpox infection of animal number 11. 
 
  
Figure 9. Single umbilicated vesicular lesions in the inguinal and axillary regions (arrows) after IN 
calpox infection of animal number 24. 
 
 
Figure 10. Severe focal vesicular dermatitis with marked intraepidermal haemorrhage after IN calpox 
infection of animal number 14. HE. Bar, 200 μm. 
 
  
Figure 11. Severe focal vesicular dermatitis with marked intraepidermal haemorrhage and numerous 
intracytoplasmic inclusion bodies after IN calpox infection of animal number 16. HE. Bar, 200 μm. 
 
 
Figure 12. Virus antigen within infected epithelial cells (arrows) after IN calpox infection of animal 
number 11. IHC. Bar, 50 μm. 
 
  
Figure 13. Virus antigen within infected basal epithelial cells of a sebaceous gland (arrows) after IN 
calpox infection of animal number 11. IHC. Bar, 50 μm. 
 
 
Figure 14. Intracytoplasmic inclusion bodies containing virus particles in the skin of animal number 11. 
TEM. Bar, 10 μm. 
 
  
Figure 15. Higher magnification of an inclusion body releasing virus particles. Skin of animal number 
11. TEM. Bar, 1 μm. 
 
